Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $19.3000 (-3.16%) ($18.6000 - $19.9700) on Fri. May. 15, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.83% (three month average) | RSI | 76 | Latest Price | $19.3000(-3.16%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.5% a day on average for past five trading days. | Weekly Trend | TGTX advances 27% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(58%) ARKK(55%) IBB(54%) IWO(54%) | Factors Impacting TGTX price | TGTX will decline at least -4.415% in a week (0% probabilities). VIXM(-33%) VXX(-32%) UUP(-16%) DRIV(-2%) XLC(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -4.415% (StdDev 8.83%) | Hourly BBV | 0 () | Intraday Trend | 2.7% | | | |
|
5 Day Moving Average | $20(-3.5%) | 10 Day Moving Average | $18.69(3.26%) | 20 Day Moving Average | $15.66(23.24%) | To recent high | -6.4% | To recent low | 170.3% | Market Cap | $2.444b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |